RBBP5 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL9940650	0.43	5/20
SCHEMBL469241	0.76	4/20
SCHEMBL14706086	0.76	4/20
SCHEMBL5184990	0.56	4/20
SCHEMBL4561846	0.48	4/20
SCHEMBL10252718	0.47	4/20
SCHEMBL805652	0.69	3/20
SCHEMBL4727574	0.54	3/20
SCHEMBL8463775	0.54	3/20
SCHEMBL14905923	0.54	3/20
SCHEMBL13976438	0.52	3/20
SCHEMBL13978308	0.52	3/20
SCHEMBL13986294	0.51	3/20
SCHEMBL14454564	0.51	3/20
SCHEMBL804176	0.50	3/20
SCHEMBL14905981	0.50	3/20
SCHEMBL10249256	0.45	3/20
SCHEMBL9106857	0.44	3/20
SCHEMBL9940605	0.43	3/20
SCHEMBL9105267	0.43	3/20

Clinical trials — most relevant to RBBP5 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in Egypt	PHASE4	COMPLETED
Management of Retinitis Pigmentosa Via Combination of Wharton's Jelly-derived Mesenchymal Stem Cells and Magnovision	PHASE3	COMPLETED
Safety and Efficacy of BMS-986504 in Unresectable Malignant Peripheral Nerve Sheath Tumor	PHASE1/PHASE2	NOT_YET_RECRUITING
Avelumab, Palbociclib and Axitinib in Advanced RCC	PHASE2	WITHDRAWN
Targeted Therapy With CDK4/6 Inhibitors in Chemo-Refractory, Rb Wild-Type Extensive SCLC	PHASE2	COMPLETED
A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL	PHASE1/PHASE2	RECRUITING
Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers	PHASE1/PHASE2	COMPLETED
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS	PHASE2	COMPLETED
A Phase I Study of Systemic Gene Therapy With SGT-94 in Patients With Solid Tumors	PHASE1	COMPLETED
An Exploratory Biomarker Study of ARQ 501 in Patients With Advanced Solid Tumors	PHASE1	COMPLETED
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck	PHASE1	COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome	PHASE1	COMPLETED
Novel Molecular Targets and Innovative Therapeutic Perspective in Medulloblastoma	EARLY_PHASE1	RECRUITING
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics	nan	UNKNOWN
Genetic Analysis of Hereditary Prostate Cancer	nan	COMPLETED
Cyclin-dependent Kinase Inhibitor 2A (Placental Senescence Marker) on Labor-related Signals	nan	UNKNOWN
Beliefs, Attitudes, and Response to Genetic Testing in SarcomaPatients	nan	RECRUITING
Studying Health Outcomes After Treatment in Patients With Retinoblastoma	nan	RECRUITING
Study of Proteins in Head and Neck Cancer Cells	nan	COMPLETED
Profiles of Expression in HPV+ Versus HPV Head and Neck Cancers	nan	UNKNOWN
Cognitive Functioning and Health Related Quality of Life in Retinoblastoma Survivors	nan	ENROLLING_BY_INVITATION
New Genes Involved in Molecular Etiology of Rett Syndrome Through DNA Microarray Comparative Genomic Hybridization	nan	COMPLETED
Retinoblastoma Biomarker Study	nan	COMPLETED
Autophagy in Systemic Lupus Erythematosus	nan	UNKNOWN
Feasibility of Generating Pluripotent Stem Cells From Patients With Familial Retinoblastoma	nan	COMPLETED
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia	nan	UNKNOWN
Molecular Analysis of Retinoblastoma	nan	COMPLETED
Telomeres Length in Israeli Fibrotic ILD Patients	nan	ENROLLING_BY_INVITATION
Gene Expression Variation and Implant Wound Healing Among Smokers and Diabetics	nan	COMPLETED
Diagnosis of RSTS: Identification of the Acetylation Profiles as Epigenetic Markers for Assessing Causality of CREBBP and EP300 Variants.	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a RBBP5 binder may also engage these)

Protein	Name	Similarity
Q8BX09	—	1.000	Q8BX09 →
Q9VPH8	—	0.998	Q9VPH8 →
Q3UMY5	—	0.997	Q3UMY5 →
Q09309	—	0.996	Q09309 →
Q09589	—	0.993	Q09589 →
Q652L2	—	0.993	Q652L2 →
O17468	—	0.993	O17468 →
Q6DIP5	—	0.992	Q6DIP5 →
Q2HJE1	—	0.992	Q2HJE1 →
Q8K3E5	—	0.992	Q8K3E5 →
Q6NL34	—	0.992	Q6NL34 →
Q6GM71	—	0.992	Q6GM71 →
Q7TMQ7	—	0.992	Q7TMQ7 →
Q9VKK2	—	0.991	Q9VKK2 →
Q84JM4	—	0.991	Q84JM4 →
F4IH25	—	0.991	F4IH25 →
Q9LXN4	—	0.991	Q9LXN4 →
A0A2R8QPS5	—	0.991	A0A2R8QPS5 →
Q5E915	—	0.991	Q5E915 →
WDR91	WD repeat-containing protein 91	0.991	landscape →
D3ZA12	—	0.991	D3ZA12 →
Q5R6T6	—	0.990	Q5R6T6 →
Q22006	—	0.990	Q22006 →
NFKB1	Nuclear factor NF-kappa-B p105 subunit	0.990	landscape →
Q6C710	—	0.990	Q6C710 →
A3KFM7	—	0.990	A3KFM7 →
Q5RE88	—	0.990	Q5RE88 →
Q6TEN6	—	0.990	Q6TEN6 →
KAT8	Histone acetyltransferase KAT8	0.990	landscape →
KDM5B	Lysine-specific demethylase 5B	0.990	landscape →